Prevention of drug-induced liver injury in patients with pulmonary tuberculosis and chronic hepatitis C

D. Ivanova (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), D. Kudlay (Moscow, Russian Federation), N. Nikolenko (Moscow, Russian Federation), L. Slogotskaya (Moscow, Russian Federation), Y. Garmash (Moscow, Russian Federation)

Source: International Congress 2019 – Clinical problems from non-malignant pleural disease to hypoventilation
Session: Clinical problems from non-malignant pleural disease to hypoventilation
Session type: Poster Discussion
Number: 2024
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Ivanova (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), D. Kudlay (Moscow, Russian Federation), N. Nikolenko (Moscow, Russian Federation), L. Slogotskaya (Moscow, Russian Federation), Y. Garmash (Moscow, Russian Federation). Prevention of drug-induced liver injury in patients with pulmonary tuberculosis and chronic hepatitis C. 2024

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical-evolutive aspects of pulmonary tuberculosis at patients with chronic hepatitis
Source: Annual Congress 2007 - Tuberculosis
Year: 2007


Interstitial lung involvement in patients with chronic HCV hepatitis
Source: Eur Respir J 2006; 28: Suppl. 50, 744s
Year: 2006

Management of tuberculosis in patients with chronic liver dysfunction
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007


The prevalence rate of chronic hepatitis B and C among pulmonary TB patients
Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups
Year: 2008

The role of hepatitis C virus infections in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 333s
Year: 2005

Clinical and morphological outcomes of pulmonary tuberculosis concurrent with chronic hepatitis
Source: Eur Respir J 2006; 28: Suppl. 50, 13s
Year: 2006

Hepatopulmonary syndrome in non-cirrhotic patients with chronic viral hepatitis
Source: International Congress 2015 – Pulmonary hypertension in lung disease
Year: 2015


Sarcoidosis associated with interferon-α therapy for chronic hepatitis C
Source: Eur Respir J 2006; 28: Suppl. 50, 541s
Year: 2006

COVID19 coinfection exacerbates lung inflammation in TB patients.
Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities
Year: 2021


Diagnosis of latent tuberculosis infection in patients with chronic liver disease undergoing liver transplantation: performance of the new IFN-γ-based assays
Source: Eur Respir J 2007; 30: Suppl. 51, 752s
Year: 2007

A case of acute interstitial pneumonia which developed during the interferon and ribavirin treatment for chronic hepatitis C
Source: Eur Respir J 2005; 26: Suppl. 49, 84s
Year: 2005

Impact of pulmonary tuberculosis infection on chronic obstructive pulmonary disease
Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases
Year: 2011

Pulmonary gas exchange and vascular abnormalities in noncirrhotic chronic hepatitis
Source: Annual Congress 2007 - Mechanisms of exercise intolerance in cardiorespiratory disease
Year: 2007


Results of treatment of patients with pulmonary tuberculosis combined with HIV infection and hepatitis
Source: International Congress 2018 – Tuberculosis comorbidities
Year: 2018

The treatment of acute respiratory viral infections in a patients with a chronic obstructive pulmonary disease
Source: Annual Congress 2012 - Fungal, viral and other infections
Year: 2012


Respiratory viral infections in Iranian patients with exacerbation of chronic obstructive pulmonary disease
Source: Annual Congress 2010 - Bronchiectasis and respiratory infections caused by Pseudomonas
Year: 2010

Interferon inducer in treatment of acute respiratory viral infections in patients with chronic obstructive pulmonary disease
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014

Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2002; 20: Suppl. 38, 354s
Year: 2002

Treatment and prevention of acute respiratory viral infections in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Viral infections
Year: 2013

Association between influenza vaccination and the occurrence of acute exacerbation in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020